Mergers and Acquisitions

Johnson & Johnson buys Momenta Pharmaceuticals for $6.5 billion. The deal will strengthen J&J's leading position in the field of immune-mediated diseases. It will include all rights to Nipocalimab, a best-in-class drug. The deal is scheduled to close by the end of this year.